Therefore, blocking Drp1-dependent mitochondrial fission, MFF, or increasing Mfn2 levels, increasing mitophagy receptor density on the mitochondria, or decreasing VDAC1 monoubiquitination are viable therapeutic options for several types of malignancies, including hematologic malignancies, as discussed later. The gene discussed is DNM1L; the disease is cancer.